NASDAQ OMX

White Rabbit CEO to Lead Discussion On The Future Of Digital Video at Berlin International Film Festival 2018

Dela

Blockchain, New Methods of Online Distribution, And Artist Compensation Major Themes At The 68th Annual Berlinale Film Festival

OSLO, Norway, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Award-winning film producer and expert on the issue of content distribution, Alan R. Milligan, announced today he will moderate an exclusive panel on Monday, February 19, 2018 examining the "New Ways of Online Distribution" featuring Bobby Allen (MUBI, UK), Jonathan Hild (Pantaflix, DE), Philip Hoffman (Rushlake Media, DE), and Pierre-Alexandre Labelle (Under the Milky Way, FR/US). Later that day, Milligan will participate in an interactive roundtable of film producers titled "Let's Change With Blockchain", where the technology's viability and global impact will be debated.

Milligan founded White Rabbit in 2017 to solve the failing business model of digital distribution of film and television, making content legally accessible to everyone. White Rabbit is a new browser plugin that accesses the global content library and recognizes the content being streamed without the need to subscribe to any one site like Hulu or Netflix. Smart contracts then enable a transaction in the form of White Rabbit Tokens (WRT) and immediately transfer payment to rights holders, offering a transparent and instant monetization model for content producers. The company poses a strong challenge to corporate studios and entertainment giants, with the goal to award fair compensation to independent filmmakers and reduce illegal piracy.

"Research shows 60 percent of illegal streamers are willing to pay if they have access to content, but we are not giving them the option," said Alan R. Milligan, Founder and CEO of White Rabbit. "No other industry deliberately blocks its fans from accessing its product like entertainment. Instead of turning our fans into criminals, the industry needs to separate between pirates and dedicated fans by allowing them to reward content creators directly from wherever they choose to stream."

White Rabbit's whitelist, an advanced registration for its token sale, is currently open to pre-sale applicants, with plans to issue its minimum viable product (MVP) in March 2018. Investors, developers and creatives interested in learning more can visit https://www.whiterabbit.one/ and sign up for the newsletter.

ABOUT WHITE RABBIT
White Rabbit is a browser plugin that aims to resolve the failing business model of digital distribution of film and television series. By offering a peer to peer tokenized system powered by blockchain technology, users can access any content globally, reduce cost by paying producers and creatives directly, revenue share with streaming sites to encourage an innovative streaming market and offer a transparent and instant monetization model for producers, investors, artists and entertainers. White Rabbit is headquartered in Oslo, Norway and backed by prominent advisors including Gregory Carson (Luxbright, Blockhead Capital), Jon Ramvi (Blockchangers), Hans Clemetsen (Javelin Corporate Services), Alexander Hagerup (Vic.ai, VS Ventures), Tom Emil Olsen (KIND), and Michael Terpin (CoinAgenda, BitAngels). Visit us at https://www.whiterabbit.one/ or join the Telegram group here.

MEDIA CONTACT: Transform Group, whiterabbit@transform.pr.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: White Rabbit via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress25.5.2018 07:45Pressmeddelande

CALGARY, Alberta, May 24, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Friday, May 25, 2018, at the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Copenhagen, Denmark, the Company is supporting a symposium titled: "Epigenetics in CKD & CVD: A potential breakthrough therapy?" The symposium highlights the role of epigenetics and BET-inhibition in chronic kidney disease and cardiovascular disease, especially in patients with diabetes mellitus, and the significant unmet need that still exists in this patient population. The symposium is co-chaired by Vincent M. Brandenburg, MD - Nephrologist, Aachen, Germany and Kamyar Kalantar-Zadeh, MD - UC Irvine School of Medicine, Irvine, CA, USA, both leading scientists also serving as advisors to Resverlogix's Renal program. The speakers and agenda are as follows: Introduction Vincent M. Brandenburg, MD - University Hospital of the RWTH

Atico Reports Consolidated Financial Results for the First Quarter of 201824.5.2018 22:30Pressmeddelande

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 24, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX.V:ATY) (OTC:ATCMF) today announced its financial results for the three months ended March 31, 2018, posting a net income of $0.4 million. Fernando E. Ganoza, CEO and Director, commented, "The strong production and all-in sustaining cash cost of $1.85 achieved this quarter is not reflected in the financial results as a large concentrate shipment was delayed to the second quarter, along with the revenue associated with those tonnes. The shipping schedule is expected to stabilize during the second quarter, where we will then benefit from the additional shipped concentrate and recognized revenue. We anticipate strong financial results in the next quarter." Mr. Ganoza continued, "Our emphasis will continue to be on further strengthening our balance sheet, improving production costs and most importantly regional

Elemica Reports Double Digit Network Growth and Announces New Product Innovations in First Quarter 201824.5.2018 18:18Pressmeddelande

Helping Process Manufacturers Undergo Digital Transformation Leads to Introduction of New Transformative Solutions WAYNE, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, announces the company's first quarter results of 2018 highlighting substantial network growth and new product innovations. The Elemica Digital Supply Network had significant network expansion in the first quarter with traffic growing 10 percent year-over-year in Q1. Shipment traffic grew substantially based on new product expansions of Elemica Trace. "Elemica's growth can be attributed to our clients needing our expertise and technology to undergo a Digital Transformation that connects, automates, anticipates and transforms their enterprise for their business growth initiatives," said John Blyzinskyj, CEO of Elemica. "Our digital supply network enables businesses to grow their top and bottom lines, mitigate risk and improve customer satisfaction ac

Luxembourg Announced as SNOMED International's Newest Member24.5.2018 15:16Pressmeddelande

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member. Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International. With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them h

SEMAFO Signs Underground Mining Services Contract with AUMS24.5.2018 14:00Pressmeddelande

MONTREAL, May 24, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports that it has signed a mining services contract with African Underground Mining Services ("AUMS") to provide turnkey mining services for Siou underground. AUMS is a well-known and reputable mining contractor with underground experience in Burkina Faso and across Africa. Under the mining services contract, AUMS will be responsible for supplying the mining fleet and a skilled labour force for Siou underground in addition to ensuring development, production and auxiliary services. SEMAFO will provide technical services including geology and engineering as well as leveraging the existing surface infrastructure at Mana. The mining services contract has a term of 70 months. The economic terms of the mining services contract are consistent with the economics presented in the Mana pre-feasibility study filed March 29, 2018 on SEDAR. Preparatory work has already commenced on Siou underground with full project deplo

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors24.5.2018 13:00Pressmeddelande

- IND Accepted in April by the U.S. FDA for MCLA-158 - UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the first patient has been dosed in a Phase 1, first-in human clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer. The trial will be conducted in Europe, where several Clinical Trial Applications (CTAs) have been approved to date. The Company also announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MCLA-158, which was accepted by the FDA in April 2018. With this acceptance, Merus plans to open additional sites for this trial in the United States. MCLA-158 is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal grow

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum